GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Race for first-to-market NASH therapy heats up, says GlobalData

Following the FDA’s announcement to review Intercept Pharmaceuticals’ resubmission of its new drug application (NDA) for obeticholic acid (OCA) in patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH); Sravani Meka, Senior Immunology Analyst at GlobalData, a leading data and analytics company, offers her view: “The race for a first-to-market therapy in NASH has […]
Read more

Travel and tourism industry deal activity sinks by 60.4% YoY in February 2023, reveals GlobalData

The global travel and tourism industry, which has been struggling to rebound from the COVID-19 pandemic induced slowdown, is facing another setback with a significant drop in deal activity. The industry, which relies heavily on investment and strategic partnerships, saw a steep year-on-year (YoY) 60.4% decline in deal activity in February 2023, reveals GlobalData, a […]
Read more

Credit Suisse rescue sees global private banking space become worryingly concentrated with 6.2% of global market share in one bank, says GlobalData

Following the news that UBS has agreed to buy crisis hit Credit Suisse; Andrew Haslip, Head of Wealth Management at GlobalData, offers his view: “While the deal is troubling for several reasons, in terms of the private wealth management space it creates a superpower that could dominate the industry. The combination of Switzerland’s two leading […]
Read more

Global deal activity plummets by 43.1% YoY in February 2023, reveals GlobalData

Global deal activity across all regions and types suffered a massive 43.1% decline in February 2023 as venture capital investors grapple with the uncertain geopolitical tensions, lower GDP growth, inflation, and rising interest rates, according to GlobalData, a leading data and analytics company. An analysis of GlobalData’s Financial Deals Database reveals that global deal volume […]
Read more

In vitro diagnostics to help cancer patients in Japan by supporting personalized oncology medicine, says GlobalData

Japan’s personalized medicine service provider Riken Genesis has recently collaborated with cancer intelligence firm C2i Genomics to make AI-powered whole-genome minimal residual disease (MRD) cancer detection technology “C2inform MRD” available across Japan. Such in vitro diagnostics (IVD)-oncology solutions help physicians not only in precise diagnosis but also aid in prescribing rational medications. Thus, the exceeding […]
Read more

Spring Budget spending boost for defence and childcare leaves little for wider public services, but lead to greater share for MoD of the £20 billion UK public sector ICT market, says GlobalData

Following the UK Chancellor Jeremy Hunt’s announcements of more funding for defence and childcare as part of the 2023 Spring Budget; Robert Stoneman, Service Director at GlobalData, a leading data and analytics company, offers his view: “Like the 2022 Autumn Statement, this again lays bare the stark divisions in public spending priorities driven by the […]
Read more

Long road ahead for non-statin therapies in Australia dyslipidemia treatment space, says GlobalData

Esperion Therapeutics’ non-statin therapy “bempedoic acid” has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in […]
Read more
1 … 112 113 114 115 116 … 209